Incidental Discovery of Hepatocellular Carcinoma on 18F-PSMA PET CT Performed for Prostate Cancer Reassessment
Prostate-specific membrane antigen positron emission tomography (PSMA PET) has been approved by the Food and Drug Administration (FDA) to identify prostate cancer in the setting of biochemical recurrence but can also identify other malignancies. 18F-PSMA PET has not been studied as a potential tool...
Saved in:
Main Authors: | Lauren Hekman, Eva Napierkowski, Natalie C. Hartman, Jeffrey L. Ellis, Robert H. Wagner, Davide Bova, Maria M. Picken, Robert C. Flanigan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-01-01
|
Series: | Case Reports in Surgery |
Online Access: | http://dx.doi.org/10.1155/2023/1458175 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PSMA PET/CT Identifies Intrapatient Variation in Salivary Gland Toxicity From Iodine-131 Therapy
by: Vineet Mohan MSc, et al.
Published: (2020-07-01) -
The impact of preliminary patient hydration on physiological [18F]PSMA-1007 uptake in the urinary bladder on PET/CT
by: T. L. Antonevskaya, et al.
Published: (2024-06-01) -
Which PSMA PET/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study
by: Le Ma, et al.
Published: (2025-01-01) -
Incidental Discovery of Duodenal Kaposi Sarcoma
by: Rangesh Modi, et al.
Published: (2025-01-01) -
Relating proton LETd to biological response of parotid and submandibular glands using PSMA-PET in clinical patients
by: Dirk Wagenaar, et al.
Published: (2025-05-01)